NCT07200089 - Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

October 10, 2027

Study Completion Date

July 31, 2028

Conditions

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory

Interventions

DRUG

NT-I7

NT-I7 will be supplied by NeoImmuneTech Inc

DRUG

Placebo

Placebo will be supplied by NeoImmuneTech Inc

BIOLOGICAL

B-cell Maturation Antigen (BCMA) CART-T therapy

Standard of care

Trial Locations (1)

Washington University School of Medicine, St Louis